Tysabri Observational Program
Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Methylprednisolone During the Switch Between Natalizumab and Fingolimod
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
† Study has passed its completion date and status has not been verified in more than two years.